Biblio

Author [ Keyword(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Animals
Schätzlein AG.  2001.  Non-viral vectors in cancer gene therapy: principles and progress.. Anticancer Drugs. 12(4):275-304.
Brown MD, Gray AI, Tetley L, Santovena A, Rene J, Schätzlein AG, Uchegbu IF.  2003.  In vitro and in vivo gene transfer with poly(amino acid) vesicles.. J Control Release. 93(2):193-211.
Brownlie A, Uchegbu IF, Schätzlein AG.  2004.  PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility.. Int J Pharm. 274(1-2):41-52.
Dufès C, Muller J-M, Couet W, Olivier J-C, Uchegbu IF, Schätzlein AG.  2004.  Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.. Pharm Res. 21(1):101-7.
Gunaratnam M, de la Fuente M, Hampel SM, Todd AK, Reszka AP, Schätzlein A, Neidle S.  2011.  Targeting pancreatic cancer with a G-quadruplex ligand.. Bioorg Med Chem. 19(23):7151-7.
Schätzlein AG, Zinselmeyer BH, Elouzi A, Dufès C, Chim YTsz A, Roberts CJ, Davies MC, Munro A, Gray AI, Uchegbu IF.  2005.  Preferential liver gene expression with polypropylenimine dendrimers.. J Control Release. 101(1-3):247-58.
Uchegbu IF, Double JA, Turton JA, Florence AT.  1995.  Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse.. Pharm Res. 12(7):1019-24.
Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF.  2012.  A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.. Mol Pharm. 9(6):1665-80.
Arunothayanun P, Turton JA, Uchegbu IF, Florence AT.  1999.  Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes.. J Pharm Sci. 88(1):34-8.
Dufès C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier J-C, Muller J-M.  2004.  Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.. Int J Pharm. 285(1-2):77-85.
Chisholm EJ, Vassaux G, Martin-Duque P, Chevre R, Lambert O, Pitard B, Merron A, Weeks M, Burnet J, Peerlinck I et al..  2009.  Cancer-specific transgene expression mediated by systemic injection of nanoparticles.. Cancer Res. 69(6):2655-62.
Kan PLee, Gray AI, Tetley L, Converse CA, Schätzlein AG, Uchegbu IF.  2005.  Tumour gene expression from C12 spermine amphiphile gene delivery systems.. J Drug Target. 13(6):345-57.
Uchegbu IF.  2006.  Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery.. Expert Opin Drug Deliv. 3(5):629-40.
Schatzlein A, Cevc G.  1998.  Non-uniform cellular packing of the stratum corneum and permeability barrier function of intact skin: a high-resolution confocal laser scanning microscopy study using highly deformable vesicles (Transfersomes).. Br J Dermatol. 138(4):583-92.
Luciani A, Olivier J-C, Clement O, Siauve N, Brillet P-Y, Bessoud B, Gazeau F, Uchegbu IF, Kahn E, Frija G et al..  2004.  Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes.. Radiology. 231(1):135-42.
Mazza M, Uchegbu IF, Schätzlein AG.  2008.  Cancer and the blood-brain barrier: 'Trojan horses' for courses? Br J Pharmacol. 155(2):149-51.
Dufès C, Uchegbu IF, Schätzlein AG.  2005.  Dendrimers in gene delivery.. Adv Drug Deliv Rev. 57(15):2177-202.
Uchegbu IF, Siew A.  2013.  Nanomedicines and nanodiagnostics come of age.. J Pharm Sci. 102(2):305-10.
Uchegbu IF.  2004.  Drug transport and drug delivery--the Midnight Sun meeting.. IDrugs. 7(8):743-5.
Siew A, Le H, Thiovolet M, Gellert P, Schätzlein A, Uchegbu I.  2012.  Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles.. Mol Pharm. 9(1):14-28.
Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G.  1998.  Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.. Biochim Biophys Acta. 1368(2):201-15.
Uchegbu IF.  2005.  Applying advanced delivery technologies to enable and improve drug development. 8-9 December 2004, London, UK.. IDrugs. 8(2):112-4.
Sludden J, Uchegbu IF, Schätzlein AG.  2000.  The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution.. J Pharm Pharmacol. 52(4):377-82.
Lalatsa A, Schätzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J, Uchegbu IF.  2015.  Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.. J Control Release. 197:87-96.
Garrett NLaura, Lalatsa A, Uchegbu I, Schätzlein A, Moger J.  2012.  Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy.. J Biophotonics. 5(5-6):458-68.

Pages